Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

New beclomethasone formulation cleared for marketing

July 5, 1996

Trials terminated for HyperGAM+ for Pseudomonas lung infections

June 28, 1996

FK-506 undergoes phase II trials

June 28, 1996

Adenosine A3 antagonists from Merck & Co.

June 28, 1996

Eisai's ER-27319: Potential in treating allergic diseases

June 28, 1996

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Abbott discloses 5-lipoxygenase inhibitors

June 28, 1996

Leukotriene biosynthesis inhibitors from Merck Frosst

June 28, 1996

Proctor & Gamble acquires Dura products

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.